aripiprazole has been researched along with Body Weight in 49 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 23 (46.94) | 29.6817 |
| 2010's | 25 (51.02) | 24.3611 |
| 2020's | 1 (2.04) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, Z; Gao, T; Huang, B; Huang, Z; Pu, C; Shi, C; Yu, X; Zhang, D; Zheng, Y; Zhou, E; Zhou, T | 1 |
| Demlova, R; Drazanova, E; Horska, K; Karpisek, M; Kasparek, T; Kotolova, H; Ruda-Kucerova, J | 1 |
| Crespo-Facorro, B; Díaz Martínez, Á; Ortiz-García de la Foz, V; Pérez-Iglesias, R; Suárez Pinilla, P; Vázquez-Bourgon, J | 1 |
| Bernardini, R; Biganzoli, E; Bravaccio, C; Capuano, A; Carnovale, C; Clementi, E; Marano, G; Molteni, M; Nobile, M; Pisano, S; Pozzi, M; Radice, S; Rafaniello, C; Rizzo, R; Rossi, F | 1 |
| Berk, M; Ghanizadeh, A; Sahraeizadeh, A | 1 |
| Forbes, RA; Mankoski, R; Manos, G; Marcus, R; Marler, S; McQuade, R; Stockton, G | 1 |
| Singh, KP; Tripathi, N | 1 |
| Buchanan, RW; Newcomer, JW; Weiden, PJ | 1 |
| Liu, J; Meng, X; Xia, SY; Yu, H; Zhang, P; Zhang, YR | 1 |
| Gorczyca, P; Rykaczewska-Czerwińska, M; Sobiś, J; Świętochowska, E | 1 |
| Bahk, WM; Chung, S; Jeong, JH; Kim, MD; Kim, W; Lee, HB; Lee, JG; Lee, K; Park, YM; Won, S; Woo, YS; Yoon, BH | 1 |
| Bose, A; Du, Y; Ehrich, EW; Nasrallah, HA; Newcomer, JW; Risinger, R; Silverman, BL; Stankovic, S; Zummo, J | 1 |
| Carson, WH; Findling, RL; Forbes, RA; Ivanova, S; Iwamoto, T; Jin, N; Marcus, R; McQuade, RD; Nyilas, M; Robb, A | 1 |
| Terao, T | 1 |
| Archibald, D; Carson, WH; Fleischhacker, WW; Marcus, RN; McQuade, RD; Swanink, R | 1 |
| Bria, P; Janiri, L; Mazza, M; Pecora, RD; Squillacioti, MR | 1 |
| Cho, SJ; Jang, JH; Kang, DH; Kim, YK; Kwon, JS; Yoo, SY | 1 |
| Baker, RA; Kim, E; Meyer, JM; Rosenblatt, LC; Whitehead, R | 1 |
| Berman, RM; Carlson, BX; Fava, M; Marcus, RN; Nelson, CJ; Pikalov, A; Qi, Y; Thase, ME; Tran, QV; Trivedi, MH; Yang, H | 1 |
| Gebicke-Härter, PJ; Schmitt, A; Segnitz, N; Zink, M | 1 |
| Englisch, S; Inta, D; Weinbrenner, A; Zink, M | 1 |
| Kashima, H; Suzuki, T; Takeuchi, H; Uchida, H; Watanabe, K | 1 |
| Coffey, BJ; Goldman, R; Hirsch, S; Jummani, R; Lyon, GJ; Samar, S; Spirgel, A | 1 |
| Hahn, SW; Ham, BJ; Kang, RH; Lee, HY; Lee, MS; Paik, JW | 1 |
| Dewaele, P; Fleischhacker, WW; Heikkinen, ME; Hennicken, D; Kerselaers, W; Landsberg, W; Loze, JY; McQuade, RD; Olié, JP | 1 |
| Bae, KY; Kim, JM; Kim, SW; Shin, IS; Yang, SJ; Yoon, JS | 1 |
| Lee, SY; Pae, CU; Park, MH; Patkar, AA | 1 |
| Cohn, T; Faulkner, G; Mukundan, A; Remington, G | 1 |
| Breton, C; Delahaye, F; Dickes-Coopman, A; Dutriez-Casteloot, I; Guillemot, J; Laborie, C; Lesage, J; Lukaszewski, MA; Mayeur, S; Montel, V; Vieau, D | 1 |
| Hamer, RH; LaVange, LM; Lieberman, JA; McEvoy, JP; Nussbaum, AM; Perkins, DO; Ring, KD; Rosenheck, RA; Stroup, TS; Swartz, MS | 1 |
| Berge, RK; Diéguez, C; Fernø, J; Fjær, S; López, M; Lunder, N; Pavlin, T; Skrede, S; Steen, VM; Vázquez, MJ; Vidal-Puig, A | 1 |
| Diaz-Atienza, F; Gurpegui, M; Gutiérrez-Rojas, L; Jurado, D; Martínez-Ortega, JM | 1 |
| Bowden, CL; Carlson, BX; Eudicone, JM; Marcus, R; McQuade, RD; Nashat, M; Thase, ME | 1 |
| Azorin, JM; Gasquet, I; Gierski, F; Leguay, D; Lemogne, C; Limosin, F; Raucher-Chéné, D; Rouillon, F; Schuster, JP | 1 |
| Chen, CK; Hsiao, CC; Huang, YS; Ree, SC; Wang, LJ | 1 |
| Baker, RA; Carlson, BX; De Hert, M; Eudicone, JM; Fyans, P; Kemp, DE; Marler, SV; Rahman, Z | 1 |
| Ali, MW; Carson, WH; Ingenito, GG; Kane, JM; McQuade, RD; Saha, AR; Zimbroff, DL | 1 |
| Britt, CS; Daniels, AJ; Grizzle, MK; Ignar, DM; Jones, DN; Kalinichev, M; Rourke, C | 1 |
| Baldessarini, RJ; Centorrino, F; Cimbolli, P; Cincotta, SL; Fogarty, KV; Salvatore, P; Sani, G; Thompson, TA | 1 |
| Abou-Gharbia, N; Bourin, M; Carson, W; Iwamoto, T; Marcus, R; McQuade, R; Sanchez, R; Stock, E; Swanink, R; Vieta, E | 1 |
| Abou-Gharbia, N; Carson, W; Impellizzeri, C; Iwamoto, T; Kaplita, S; Marcus, R; McQuade, R; Rollin, L; Sachs, G; Sanchez, R; Stock, E | 1 |
| Borba, CP; Cather, C; Daley, TB; Evins, AE; Freudenreich, O; Goff, DC; Henderson, DC; Kunkel, L; Louie, PM; Nguyen, DD | 1 |
| Duane, DD | 1 |
| Harborne, GC; Karunakaran, K; Tungaraza, TE | 1 |
| Chrzanowski, WK; Marcus, RN; McQuade, RD; Nyilas, M; Torbeyns, A | 1 |
| Altshuler, LL; Frye, MA; Keck, PE; Leverich, GS; Martens, B; McElroy, SL; Post, RM; Stanford, K; Suppes, T | 1 |
| Carson, WH; Daniel, DG; Marcus, RN; McEvoy, JP; McQuade, RD | 1 |
| Corey-Lisle, PK; Crosby, RD; Kan, HJ; Kolotkin, RL; McQuade, RD | 1 |
| Bai, DS; Sea, HS; Seo, WS; Sung, HM | 1 |
3 review(s) available for aripiprazole and Body Weight
| Article | Year |
|---|---|
Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Drug Substitution; Dyskinesia, Drug-Induced; Evidence-Based Medicine; Humans; Lipids; Olanzapine; Patient Outcome Assessment; Piperazines; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology | 2013 |
Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Dibenzothiazepines; Drug Substitution; Fasting; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Schizophrenia; Weight Gain | 2010 |
Aripiprazole in bipolar depression: a pooled, post-hoc analysis by severity of core depressive symptoms.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Depression; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Nausea; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome; Young Adult | 2012 |
24 trial(s) available for aripiprazole and Body Weight
| Article | Year |
|---|---|
Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Dibenzothiazepines; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Thiazoles; Triglycerides; Young Adult | 2018 |
A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Body Weight; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Irritable Mood; Male; Piperazines; Quinolones; Risperidone; Treatment Outcome | 2014 |
Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Body Weight; Child; Double-Blind Method; Female; Humans; Irritable Mood; Male; Piperazines; Quinolones | 2013 |
[Treatment of antipsychotic drug-induced phlegm dampness type amenorrhea by Wuji Powder and a small dose aripiprazole: a clinical study].
Topics: Aged; Amenorrhea; Antipsychotic Agents; Aripiprazole; Body Mass Index; Body Weight; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Galactorrhea; Humans; Obesity; Piperazines; Quinolones; Waist-Hip Ratio | 2014 |
Therapeutic effect of aripiprazole in chronic schizophrenia is accompanied by anti-inflammatory activity.
Topics: Anti-Inflammatory Agents; Aripiprazole; Body Weight; C-Reactive Protein; Chronic Disease; Cytokines; Female; Humans; Insulin; Male; Middle Aged; Schizophrenia | 2015 |
Effects of switching to aripiprazole from current atypical antipsychotics on subsyndromal symptoms and tolerability in patients with bipolar disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Drug Substitution; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2016 |
Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aripiprazole; Blood Glucose; Body Weight; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Injections, Intramuscular; Lipids; Lipoproteins; Male; Middle Aged; Prolactin; Risk; Schizophrenia; Schizophrenic Psychology; Young Adult | 2016 |
A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
Topics: Administration, Oral; Adolescent; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2008 |
A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Double-Blind Method; Electrocardiography; Female; Glucose; Humans; Lipid Metabolism; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Quinolones; Schizophrenia | 2009 |
Beneficial acute antidepressant effects of aripiprazole as an adjunctive treatment or monotherapy in bipolar patients unresponsive to mood stabilizers: results from a 16-week open-label trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Depression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Headache; Humans; Lorazepam; Male; Middle Aged; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Young Adult | 2008 |
Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Body Weight; Comorbidity; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Personality Inventory; Piperazines; Quinolones; Treatment Outcome | 2008 |
Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Body Weight; Child; Dose-Response Relationship, Drug; Female; Humans; Male; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Severity of Illness Index; Tics; Tourette Syndrome; Treatment Outcome; Young Adult | 2009 |
Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Aripiprazole; Body Mass Index; Body Weight; Chemotherapy, Adjuvant; Cholesterol; Clozapine; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Treatment Outcome; Young Adult | 2010 |
Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Size; Body Weight; Diagnostic and Statistical Manual of Mental Disorders; Female; Hip; Humans; Hyperprolactinemia; Liver Function Tests; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Thiazoles; Treatment Outcome; Waist Circumference; Wakefulness; Young Adult | 2010 |
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Cholesterol; Cholesterol, LDL; Combined Modality Therapy; Dibenzothiazepines; Diet, Reducing; Drug Substitution; Exercise; Humans; Hypercholesterolemia; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risk; Risperidone; Schizophrenia; Treatment Outcome; Triglycerides | 2011 |
Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lamotrigine; Lithium; Male; Metabolic Syndrome; Middle Aged; Obesity; Overweight; Piperazines; Quinolones; Time Factors; Treatment Outcome; Triazines; Valproic Acid | 2013 |
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Double-Blind Method; Drug Administration Schedule; Electroencephalography; Female; Haloperidol; Humans; Hyperprolactinemia; Long QT Syndrome; Male; Piperazines; Placebos; Prolactin; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome | 2002 |
Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Double-Blind Method; Electrocardiography; Female; Haloperidol; Humans; Male; Middle Aged; Patient Dropouts; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome | 2005 |
Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Piperazines; Prolactin; Quinolones | 2006 |
An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Clozapine; Community Mental Health Centers; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Triglycerides | 2006 |
Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Quinolones; Recurrence; Schizophrenia; Treatment Outcome; Triglycerides | 2006 |
A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Schizophrenia | 2007 |
Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Dibenzothiazepines; Dose-Response Relationship, Drug; Europe; Female; Humans; Male; Middle Aged; Obesity; Olanzapine; Piperazines; Quality of Life; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Self Concept; Social Adjustment | 2008 |
Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Body Mass Index; Body Weight; Child; Chronic Disease; Female; Humans; Male; Piperazines; Quinolones; Tics; Tourette Syndrome; Treatment Outcome | 2008 |
22 other study(ies) available for aripiprazole and Body Weight
| Article | Year |
|---|---|
Weight changes following treatment with aripiprazole, risperidone and olanzapine: A 12-month study of first-episode schizophrenia patients in China.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Humans; Olanzapine; Risperidone; Schizophrenia; Weight Gain | 2023 |
Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Aripiprazole; Body Weight; Cytokines; Disease Models, Animal; Ghrelin; Glucagon-Like Peptide 1; Leptin; Male; Metabolic Syndrome; Poly I-C; Random Allocation; Rats, Wistar; Schizophrenia | 2017 |
Weight-Change Trajectories of Pediatric Outpatients Treated with Risperidone or Aripiprazole in a Naturalistic Setting.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Body Mass Index; Body Weight; Child; Female; Humans; Male; Outpatients; Risperidone; Weight Gain | 2019 |
Prenatal exposure of a novel antipsychotic aripiprazole: impact on maternal, fetal and postnatal body weight modulation in rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Birth Weight; Body Weight; Eating; Female; Fetal Weight; Male; Piperazines; Pregnancy; Prenatal Exposure Delayed Effects; Quinolones; Rats; Rats, Wistar | 2014 |
Unusual weight fluctuation under corticosteroid and psychotropic treatment.
Topics: Adult; Anti-Inflammatory Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Appetite; Aripiprazole; Body Weight; Cyclosporine; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Eating; Female; Humans; Mianserin; Paroxetine; Piperazines; Prednisolone; Quinolones; Sertraline; Takayasu Arteritis | 2008 |
Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Mass Index; Body Weight; Female; Humans; Korea; Male; Middle Aged; Piperazines; Prolactin; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Suicide; Young Adult | 2009 |
The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Black or African American; Blood Glucose; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Hispanic or Latino; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Obesity; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; White People; Young Adult | 2009 |
Differential expression of glutamate transporter genes after chronic oral treatment with aripiprazole in rats.
Topics: Amino Acid Transport System X-AG; Animals; Antipsychotic Agents; Aripiprazole; Astrocytes; Body Weight; Dose-Response Relationship, Drug; Gene Expression Regulation; Genetic Markers; In Situ Hybridization; Male; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Time Factors; Transcription, Genetic | 2009 |
Aripiprazole for the management of olanzapine-induced weight gain.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Central Nervous System Agents; Cholesterol; Drug Therapy, Combination; Female; Glucose; Humans; Male; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Treatment Outcome; Triglycerides; Weight Gain | 2009 |
Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: One-year follow-up study.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Body Weight; Cholesterol; Electrocardiography; Female; Follow-Up Studies; Heart; Hormones; Humans; Japan; Male; Middle Aged; Piperazines; Prolactin; Quinolones; Schizophrenia; Triglycerides | 2010 |
Trial of aripiprazole in the treatment of first-episode schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Body Weight; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Young Adult | 2010 |
A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
Topics: Age Factors; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Dibenzothiazepines; Female; Humans; Inpatients; Male; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risk; Risk Factors; Risperidone; Schizophrenia; Sex Factors; Time Factors; Weight Gain | 2011 |
Influence of prenatal undernutrition on the effects of clozapine and aripiprazole in the adult male rats: relevance to a neurodevelopmental origin of schizophrenia?
Topics: Animals; Antipsychotic Agents; Aripiprazole; Body Weight; Clozapine; Disease Susceptibility; Eating; Female; Gene Expression Regulation; Hormones; Hypothalamus; Male; Malnutrition; Nervous System; Obesity; Piperazines; Pregnancy; Prenatal Nutritional Physiological Phenomena; Quinolones; Rats; Rats, Wistar; Schizophrenia | 2011 |
Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Female; Gene Expression Regulation; Hyperphagia; Lipid Metabolism; Lipogenesis; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Triglycerides; Weight Gain | 2012 |
Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents.
Topics: Adolescent; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Benzodiazepines; Bipolar Disorder; Body Mass Index; Body Weight; Child; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Spain; Time Factors | 2011 |
Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Clozapine; Cohort Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Olanzapine; Piperazines; Prospective Studies; Quinolones; Risperidone; Schizophrenia; Weight Loss | 2012 |
Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
Topics: Adiponectin; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Female; Humans; Lipids; Male; Middle Aged; Obesity; Olanzapine; Piperazines; Prospective Studies; Psychotic Disorders; Quinolones; Weight Gain | 2013 |
Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats.
Topics: Animals; Aripiprazole; Benzodiazepines; Body Weight; Cholesterol, HDL; Fatty Acids, Nonesterified; Female; Olanzapine; Piperazines; Prolactin; Quinolones; Rats; Rats, Sprague-Dawley; Rats, Wistar; Weight Gain | 2005 |
Aripiprazole: initial clinical experience with 142 hospitalized psychiatric patients.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hospitalization; Humans; Male; Mathematical Computing; Middle Aged; Obesity; Piperazines; Product Surveillance, Postmarketing; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Schizophrenia; Treatment Outcome | 2005 |
Aripiprazole in childhood and adolescence for Tourette syndrome.
Topics: Adolescent; Adolescent Behavior; Adult; Antipsychotic Agents; Aripiprazole; Attention; Body Weight; Child; Child Behavior; Cognition; Dose-Response Relationship, Drug; Humans; Male; Piperazines; Psychomotor Agitation; Quinolones; Tourette Syndrome; Treatment Outcome | 2006 |
Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?
Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Weight; Cholesterol; Clozapine; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Quinolones; Retrospective Studies; Schizophrenia; Schizophrenic Psychology | 2007 |
Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial.
Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Patient Dropouts; Pilot Projects; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones | 2007 |